Literature DB >> 11756087

Percutaneous radiofrequency ablation of hepatic tumors during temporary venous occlusion.

T de Baere1, B Bessoud, C Dromain, M Ducreux, V Boige, N Lassau, T Smayra, B V Girish, A Roche, D Elias.   

Abstract

OBJECTIVE: We evaluated the feasibility, tolerance, and efficacy of percutaneous hepatic vein or segmental portal branch balloon occlusion during radiofrequency ablation of hepatic malignancies. SUBJECTS AND METHODS: Ten tumors were treated by percutaneous radiofrequency ablation during balloon occlusion of a hepatic vein (n = 8) or a segmental portal branch (n = 2). Venous occlusion was undertaken because the tumor was in contact with a hepatic vein (n = 3) or a portal branch (n = 1); because the tumor exceeded 35 mm in width (mean, 44 mm), which was considered the maximum size amenable to ablation in a single session (n = 2); or because of both large size and contact with a hepatic vein (n = 3) or a portal branch (n = 1).
RESULTS: Vascular occlusion was always technically possible. Radiofrequency was delivered to one to three locations (mean, 1.9 locations) with a cluster electrode. The largest axis of radiofrequency-induced lesions after ablation with the cluster needle-between 42 and 51 mm (mean, 49 mm)-was always larger than the targeted tumor. These sizes were statistically larger than in a matched control group of patients who underwent radiofrequency ablation without vascular occlusion (p < 0.0003). After a mean follow-up of 12.6 months, CT and MR imaging revealed complete destruction of nine tumors after a single radiofrequency ablation treatment; one tumor required three treatments to achieve ablation. Five patients are tumor-free 12-18 months (mean, 14.4 months) after the first radiofrequency ablation treatment, and five developed new liver metastases.
CONCLUSION: Temporary hepatic vein or portal branch occlusion during radiofrequency ablation can safely facilitate the treatment of large tumors or tumors in contact with the walls of large vessels.

Entities:  

Mesh:

Year:  2002        PMID: 11756087     DOI: 10.2214/ajr.178.1.1780053

Source DB:  PubMed          Journal:  AJR Am J Roentgenol        ISSN: 0361-803X            Impact factor:   3.959


  25 in total

1.  Radiofrequency ablation in a previously irradiated liver.

Authors:  Marc A Friedman; Rosemary Altemus; Bradford J Wood
Journal:  J Vasc Interv Radiol       Date:  2003-10       Impact factor: 3.464

Review 2.  Image-guided tumor ablation: standardization of terminology and reporting criteria.

Authors:  S Nahum Goldberg; Clement J Grassi; John F Cardella; J William Charboneau; Gerald D Dodd; Damian E Dupuy; Debra Gervais; Alice R Gillams; Robert A Kane; Fred T Lee; Tito Livraghi; John McGahan; David A Phillips; Hyunchul Rhim; Stuart G Silverman
Journal:  Radiology       Date:  2005-04-21       Impact factor: 11.105

Review 3.  Local recurrence after hepatic radiofrequency coagulation: multivariate meta-analysis and review of contributing factors.

Authors:  Stefaan Mulier; Yicheng Ni; Jacques Jamart; Theo Ruers; Guy Marchal; Luc Michel
Journal:  Ann Surg       Date:  2005-08       Impact factor: 12.969

4.  Quantitative magnetic resonance temperature mapping for real-time monitoring of radiofrequency ablation of the liver: an ex vivo study.

Authors:  Olivier Seror; Matthieu Lepetit-Coiffé; Bruno Quesson; Hervé Trillaud; Chrit T W Moonen
Journal:  Eur Radiol       Date:  2006-04-11       Impact factor: 5.315

5.  Emerging local ablation techniques.

Authors:  Michael J Stone; Bradford J Wood
Journal:  Semin Intervent Radiol       Date:  2006-03       Impact factor: 1.513

6.  The prediction of radiofrequency ablation zone volume using vascular indices of 3-dimensional volumetric colour Doppler ultrasound in an in vitro blood-perfused bovine liver model.

Authors:  Samuel Chang; Anthony C Lanctot; Martin D McCarter; Katherine M Roberts; Deborah H Glueck; Gerald D Dodd
Journal:  Br J Radiol       Date:  2016-12-07       Impact factor: 3.039

7.  Large-sized hepatocellular carcinoma (HCC): a neoadjuvant treatment protocol with repetitive transarterial chemoembolization (TACE) before percutaneous MR-guided laser-induced thermotherapy (LITT).

Authors:  Stephan Zangos; Katrin Eichler; Jörn O Balzer; Ralf Straub; Renate Hammerstingl; Christopher Herzog; Thomas Lehnert; Mathias Heller; Axel Thalhammer; Martin G Mack; Thomas J Vogl
Journal:  Eur Radiol       Date:  2006-08-08       Impact factor: 5.315

8.  Long-term survival of patients with unresectable colorectal liver metastases treated by percutaneous interstitial laser thermotherapy.

Authors:  Christopher Christophi; Mehrdad Nikfarjam; Caterina Malcontenti-Wilson; Vijayaragavan Muralidharan
Journal:  World J Surg       Date:  2004-09-29       Impact factor: 3.352

9.  Local recurrence of hepatocellular carcinoma after segmental transarterial chemoembolization: risk estimates based on multiple prognostic factors.

Authors:  Seung Hyun Park; Yun Ku Cho; Yong-Sik Ahn; Yoon-Ok Park; Jae Kyun Kim; Jin Wook Chung
Journal:  Korean J Radiol       Date:  2007 Mar-Apr       Impact factor: 3.500

10.  Adjuvant percutaneous radiofrequency ablation of feeding artery of hepatocellular carcinoma before treatment.

Authors:  Yi-Bin Hou; Min-Hua Chen; Kun Yan; Jin-Yu Wu; Wei Yang
Journal:  World J Gastroenterol       Date:  2009-06-07       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.